GalNAc-TL2 Inhibitors
GalNAc-TL2 Inhibitors are a collection of chemical compounds that directly or indirectly lead to the reduced functional activity of the enzyme GalNAc-TL2. Benzyl-2-acetamido-2-deoxy-α-D-galactopyranoside operates as a competitive inhibitor, directly occupying the active site of GalNAc-TL2, preventing the attachment of N-acetylgalactosamine to target proteins, thereby directly impeding its glycosylation function. Similarly, Acarbose acts by limiting the supply of the enzyme's sugar donor substrate, UDP-GalNAc, through its alpha-glucosidase inhibitory action, thus indirectly decreasing the glycosylating activity of GalNAc-TL2. Tunicamycin, by preventing the formation of dolichol-linked oligosaccharides, indirectly disrupts the conducive environment for GalNAc-TL2 activity within the endoplasmic reticulum. Castanospermine and Swainsonine, on the other hand, elicit a stress response due to their interference with glycoprotein processing, which could indirectly lead to a reduction in GalNAc-TL2 activity by altering the cellular focus towards correcting glycoprotein folding and processing, respectively.
Deoxynojirimycin and Deoxymannojirimycin further contribute to the inhibition of GalNAc-TL2 by targeting the maturation and trafficking of glycoproteins within the Golgi apparatus, where GalNAc-TL2 is active, through their inhibition of alpha-glucosidases and mannosidase I. Kifunensine and Nojirimycin add to this inhibitory portfolio by impacting the processing of oligosaccharides and glycoconjugate catabolism, potentially disturbing GalNAc-TL2's substrate availability and glycosylation balance. Miglustat, through its inhibition of glucosylceramide synthase, can alter the lipid composition of Golgi membranes, affecting GalNAc-TL2's localization and activity. Finally, Brefeldin A and Monensin exert their inhibitory effects by disrupting Golgi structure and ion equilibrium, respectively, creating unfavorable conditions for GalNAc-TL2's enzymatic action, resulting in a diminished glycosylation capability of the enzyme.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Benzyl-2-acetamido-2-deoxy-α-D-galactopyranoside | 3554-93-6 | sc-203427 sc-203427A | 100 mg 1 g | $350.00 $3184.00 | 2 | |
Benzyl-2-acetamido-2-deoxy-α-D-galactopyranoside acts as a competitive inhibitor for GalNAc-TL2 by mimicking the natural substrate of the enzyme. By occupying the active site, it prevents the transfer of N-acetylgalactosamine (GalNAc) to serine or threonine residues on proteins, directly diminishing GalNAc-TL2's glycosyltransferase activity. | ||||||
Acarbose | 56180-94-0 | sc-203492 sc-203492A | 1 g 5 g | $226.00 $605.00 | 1 | |
Acarbose, an alpha-glucosidase inhibitor, can indirectly inhibit GalNAc-TL2 by reducing the availability of UDP-GalNAc, the sugar donor substrate for GalNAc-T2. As acarbose interferes with carbohydrate digestion and absorption, this could lead to a decreased pool of substrates needed for GalNAc-TL2's glycosylation process. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
Tunicamycin inhibits the initial steps of N-linked glycosylation by blocking the transfer of N-acetylglucosamine-1-phosphate to dolichol monophosphate. This inhibition can indirectly diminish GalNAc-TL2 activity by disrupting the overall glycosylation environment in the endoplasmic reticulum, where GalNAc-TL2 functions. | ||||||
Castanospermine | 79831-76-8 | sc-201358 sc-201358A | 100 mg 500 mg | $184.00 $632.00 | 10 | |
Castanospermine is an inhibitor of glucosidase I and II. Its action leads to the accumulation of misfolded glycoproteins, potentially causing a stress response that diminishes the activity of other glycosyltransferases like GalNAc-TL2, due to the heightened demand to correct glycoprotein folding. | ||||||
Swainsonine | 72741-87-8 | sc-201362 sc-201362C sc-201362A sc-201362D sc-201362B | 1 mg 2 mg 5 mg 10 mg 25 mg | $138.00 $251.00 $631.00 $815.00 $1832.00 | 6 | |
Swainsonine is an inhibitor of Golgi alpha-mannosidase II. By inhibiting this enzyme, it impairs the processing of N-linked glycans, which may result in altered trafficking and localization of glycosylation enzymes including GalNAc-TL2, thus indirectly diminishing its activity in the Golgi apparatus. | ||||||
Deoxynojirimycin | 19130-96-2 | sc-201369 sc-201369A | 1 mg 5 mg | $73.00 $145.00 | ||
Deoxynojirimycin inhibits alpha-glucosidases, which could potentially decrease the processing of glycoproteins and affect the glycosylation machinery, thereby indirectly diminishing the functional activity of GalNAc-TL2 by affecting the maturation and trafficking of this enzyme within the Golgi apparatus. | ||||||
Deoxymannojirimycin hydrochloride | 84444-90-6 | sc-201360 sc-201360A | 1 mg 5 mg | $93.00 $239.00 | 2 | |
Deoxymannojirimycin acts as an inhibitor of mannosidase I, which is involved in N-linked glycan processing. By disrupting the normal processing of N-linked glycans, it may indirectly diminish the activity of GalNAc-TL2 by altering the glycosylation pathway and the proper functioning of the Golgi apparatus. | ||||||
Kifunensine | 109944-15-2 | sc-201364 sc-201364A sc-201364B sc-201364C | 1 mg 5 mg 10 mg 100 mg | $135.00 $540.00 $1025.00 $6248.00 | 25 | |
Kifunensine is a mannosidase I inhibitor that prevents the processing of high mannose-type oligosaccharides. Inhibition of this step could indirectly lead to a decrease in GalNAc-TL2 activity due to the potential mislocalization or misfolding of glycoproteins within the Golgi apparatus. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A disrupts the structure and function of the Golgi apparatus, which could indirectly inhibit GalNAc-TL2 by preventing its proper localization and functioning within the disrupted Golgi stacks. As a result, the enzyme's ability to catalyze the transfer of GalNAc to proteins may be significantly diminished. | ||||||